Showing 1 - 4 results of 4 for search 'Natalie F Reash', query time: 0.02s Refine Results
  1. 1
    Feasibility and utility of in-home body weight support harness system use in young children treated for spinal muscular atrophy: A single-arm prospective cohort study.

    Feasibility and utility of in-home body weight support harness system use in young children treated for spinal muscular atrophy: A single-arm prospective cohort study. by Megan A Iammarino, Lindsay N Alfano, Natalie F Reash, Brenna Sabo, Sara Conroy, Garey Noritz, Madalynn Wendland, Linda P Lowes

    Published 2024-01-01
    Get full text
    Article
  2. 2
    Remote Delivery of Motor Function Assessment and Training for Clinical Trials in Neuromuscular Disease: A Response to the COVID-19 Global Pandemic

    Remote Delivery of Motor Function Assessment and Training for Clinical Trials in Neuromuscular Disease: A Response to the COVID-19 Global Pandemic by Meredith K. James, Kristy Rose, Kristy Rose, Lindsay N. Alfano, Lindsay N. Alfano, Natalie F. Reash, Michelle Eagle, Linda P. Lowes, Linda P. Lowes

    Published 2021-10-01
    Get full text
    Article
  3. 3
    P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study*

    P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study* by Erin O’Rourke, Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, Linda P. Lowes, Natalie F. Reash, Megan Iammarino, Lindsay Alfano, Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, Danielle Griffin, Mark J. Hogan, Shufang Wang, Stefanie Mason, Eddie Darton, Louise Rodino-Klapac

    Published 2023-01-01
    Get full text
    Article
  4. 4
    Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy

    Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscu... by Jerry R. Mendell, Jerry R. Mendell, Jerry R. Mendell, Perry B. Shieh, Craig M. McDonald, Zarife Sahenk, Zarife Sahenk, Zarife Sahenk, Kelly J. Lehman, Linda P. Lowes, Linda P. Lowes, Natalie F. Reash, Megan A. Iammarino, Lindsay N. Alfano, Brenna Sabo, Jeremy D. Woods, Christy L. Skura, Howard C. Mao, Loretta A. Staudt, Danielle A. Griffin, Sarah Lewis, Shufang Wang, Rachael A. Potter, Teji Singh, Louise R. Rodino-Klapac

    Published 2023-07-01
    Get full text
    Article

Search Tools: